AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca, in collaboration with Parexel International, recently completed a Phase I clinical study titled An Open-label, Randomised, 2-arm, 3-period, 6-treatment Single-dose, Crossover Study Comparing the Pharmacokinetics of 2 Different Formulations of AZD4144, and Effect of Food and Omeprazole on the Pharmacokinetics of AZD4144 in Healthy Participants. The study aimed to evaluate the pharmacokinetics of two formulations of AZD4144 and the impact of food and omeprazole on its absorption in healthy individuals.
The study tested two formulations of AZD4144, an investigational drug, in tablet and oral solution forms. It also assessed the effect of omeprazole, a commonly used medication for reducing stomach acid, on AZD4144’s pharmacokinetics.
This open-label, randomized, crossover study involved two arms with different treatment sequences. Participants received single doses of AZD4144 under various conditions, including fasted and fed states, and in combination with omeprazole. The primary goal was to understand how these factors influence the drug’s absorption and processing in the body.
The study commenced on April 23, 2025, and was completed by July 22, 2025. These dates are crucial as they mark the timeline of the study’s execution and data collection, which can affect the timing of subsequent phases and regulatory submissions.
This update could influence AstraZeneca’s stock performance by providing insights into the drug’s development progress. Positive results might boost investor confidence, while any setbacks could have the opposite effect. The study’s completion also positions AstraZeneca competitively within the pharmaceutical industry as it advances its pipeline.
The study is now completed, with further details available on the ClinicalTrials portal.